FDA Drug Safety Communication: Adcetris (brentuximab vedotin)
The U.S. Food and Drug Administration (FDA) is notifying the public that two additional cases of progressive multifocal leukoencephalopathy ( PML ), a rare but serious brain infection that can result in death, have been reported with the lymphoma drug Adcetris ( brentuximab vedotin ).
Does Chemotherapy Cause Cancer to Return?
Most patients with acute myeloid leukemia will undergo chemotherapy to treat the disease. But this treatment may be causing harm as well as helping, according to a new study.
Keys to Unlocking Multiple Myeloma Resistance
People living with the blood cancer multiple myeloma typically take two drugs in combination. The problem is these drugs don't work with every person and tend to fade in effectiveness over time.
Fish Oil Possible Solution for Leukemia
You've heard about the health benefits of fish oil. What this oil contains - Omega 3 fatty acids - are good for your heart, joints, eyes and brain. Researchers think a compound found in the natural substance may be able to fight off a type of cancer.
Immune Cells Tactics: Divide and Conquer
Scientists understand the big picture of how vaccines work in the body but not all the specifics at the cellular level. Now they have discovered one more piece of the puzzle.
Waging War Against Chronic Myeloid Leukemia
A possible new front runner is emerging in the drug war against chronic myeloid leukemia ( CML ). While still considered experimental, this drug is showing itself to be a powerful agent against advanced forms of the disease.
Unlocking Chronic Myeloid Leukemia Resistance
Gleevec ( imatinib ) has transformed the treatment of chronic myeloid leukemia ( CML ). The problem is, this drug stops working at some point in many patients. A drug under development, combined with another currently available medication, may offer patients new options.
It doesn't happen commonly, though some diseases can present themselves as other diseases. Scientists now know this sometimes happens with two forms of leukemia.
Merck Announces Multiple Myeloma Drug Trial Results
Merck announced today that a Phase III study of Zolinza ( vorinostat ), for investigational use in combination with bortezomib in patients with progressive multiple myeloma , met its primary endpoint, demonstrating a 23 percent reduction in the risk of progression compared to the standard therapy of bortezomib (p=0.01).
Two Sisters Help Understand One Disease
It's well known that cancer can be passed between a donor and recipient during a transplant operation. One such exchange has actually advanced the scientific understanding of lymphoma.